Phase 3 clinical trial successfully completed

It is with immense pride that we announce the success of our Phase 3 clinical trial for the first cellular drug based on canine neonatal stem cells. This major advancement in animal health opens new perspectives for managing dogs with osteoarthritis.

The goal of this development was simple: to provide veterinarians with a treatment for osteoarthritis that offers long-term clinical benefits with maximum safety. We have successfully demonstrated this in our clinical trial, conducted under Good Clinical Practice conditions and with a robust scientific methodology.

Our first thanks go to the Vetbiobank team, whose years of hard work in developing this drug have now been crowned with this remarkable success. We are also grateful to the Argenta San Sebastian team (Spain) for conducting this study in record time with the involvement of investigator veterinarians in Spain and France. Thank you also to the dog owners who participated in this study.

This innovative drug offers a new therapeutic dimension to veterinarians, improving the quality of life for our loyal companions suffering from osteoarthritis. We believe veterinarians will be eager to apply their medical and technical expertise to administer this product into the joint, similar to treatments for humans. We look forward to continuing our efforts with the veterinary community to make this treatment available to all dogs in need.

Vetbiobank is a pharmaceutical establishment (Lyon), specializing in the development and bioproduction of cellular drugs for veterinary medicine, aimed at treating chronic inflammatory diseases in cats, dogs, and horses.